WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2005016286) PYRAZINE MODULATORS OF CANNABINOID RECEPTORS
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2005/016286    International Application No.:    PCT/US2004/026599
Publication Date: 24.02.2005 International Filing Date: 16.08.2004
IPC:
A61K 31/4965 (2006.01), A61K 31/497 (2006.01), C07D 241/00 (2006.01), C07D 241/02 (2006.01)
Applicants: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road, Princeton, NJ 08543-4000 (US) (For All Designated States Except US).
ELLSWORTH, Bruce, A. [US/US]; (US) (For US Only).
SUN, Chongqing [US/US]; (US) (For US Only).
PENDRI, Annapurna [IN/US]; (US) (For US Only)
Inventors: ELLSWORTH, Bruce, A.; (US).
SUN, Chongqing; (US).
PENDRI, Annapurna; (US)
Agent: DUNCAN, Sammy; Bristol-Myers Squibb Company, P.O. Box 4000, Princeton, NJ 08543-4000 (US)
Priority Data:
60/495,807 15.08.2003 US
10/917,199 12.08.2004 US
Title (EN) PYRAZINE MODULATORS OF CANNABINOID RECEPTORS
(FR) MODULATEURS PYRAZINIQUES DE RECEPTEURS CANABINOÏDES
Abstract: front page image
(EN)The present application describes compounds according to Formula (I), wherein A, G1, G2 and R1 are described herein. Additionally, the present application describes pharmaceutical compositions comprising at least one compound according to Formula I and optionally one or more additional therapeutic agents. Finally, the present application describes methods of treatment using the compounds according to Formula (I) both alone and in combination with one or more additional therapeutic agents.
(FR)La présente invention concerne des composés représentés par la formule (I) dans laquelle A, G1, G2 et R1 sont comme définis dans le descriptif. De plus, cette invention concerne des compositions pharmaceutiques renfermant au moins un des composés de formule (I) et éventuellement un ou plusieurs agents thérapeutiques supplémentaires. Sont décrites enfin des méthodes de traitement au moyen des composés de formule (I) pris soit seuls, soit en combinés à un ou plusieurs autres agents thérapeutiques.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)